Months after big financing round, Touchlight signs supply agreement for Versameb's pipeline

Josh Sullivan

A UK-based CDMO has landed a supply agreement with Versameb to provide its doggybone DNA for the company’s pipeline, including for its lead candidate to treat stress urinary incontinence.

Touchlight will supply Versameb with its enzymatic DNA as the biotech prepares to enter VMB-100 into Phase I clinical trials in the second half of this year. The deal will allow Versameb to utilize Touchlight’s dbDNA, also called doggybone DNA, for all future pipeline products.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

BECOME A PREMIUM SUBSCRIBER

TRENDING NOW

Months after big financing round, Touchlight signs supply agreement for Versameb's pipeline

Josh Sullivan

Unlock this article instantly by becoming a free subscriber.

Updated: FDA approves Pfizer’s hemophilia B gene therapy, with $3.5M price tag

UCB makes major management changes; Bristol Myers’ ADC partner tops list of new CEOs

The next generation of AI biotechs is here. Can they deliver on the hype?

Gilead leans on CymaBay liver drug, Trodelvy readouts and long-active PrEP yet to come this year

AbbVie beats first-quarter expectations, but Humira guidance leaves analysts confused

Bristol Myers outlines ‘about 12’ pipeline cuts as it executes major cutbacks

Months af­ter big fi­nanc­ing round, Touch­light signs sup­ply agree­ment for Ver­same­b's pipeline

Josh Sullivan

Unlock this article instantly by becoming a free subscriber.

more like this

Up­dat­ed: FDA ap­proves Pfiz­er’s he­mo­phil­ia B gene ther­a­py, with $3.5M price tag

UCB makes ma­jor man­age­ment changes; Bris­tol My­ers’ ADC part­ner tops list of new CEOs

The next gen­er­a­tion of AI biotechs is here. Can they de­liv­er on the hype?

Gilead leans on CymaBay liv­er drug, Trodelvy read­outs and long-ac­tive PrEP yet to come this year

Ab­b­Vie beats first-quar­ter ex­pec­ta­tions, but Hu­mi­ra guid­ance leaves an­a­lysts con­fused

Bris­tol My­ers out­lines ‘about 12’ pipeline cuts as it ex­e­cutes ma­jor cut­backs

Months after big financing round, Touchlight signs supply agreement for Versameb's pipeline

Updated: FDA approves Pfizer’s hemophilia B gene therapy, with $3.5M price tag

UCB makes major management changes; Bristol Myers’ ADC partner tops list of new CEOs

The next generation of AI biotechs is here. Can they deliver on the hype?

Gilead leans on CymaBay liver drug, Trodelvy readouts and long-active PrEP yet to come this year

AbbVie beats first-quarter expectations, but Humira guidance leaves analysts confused

Bristol Myers outlines ‘about 12’ pipeline cuts as it executes major cutbacks